comparison of the effectiveness of placentrex, hyaluronidase, and dexamethasone in the treatment of Oral submucous fibrosis.
Not Applicable
Completed
- Conditions
- Health Condition 1: 3- Administration
- Registration Number
- CTRI/2024/01/061403
- Lead Sponsor
- Jay Goyal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 160
Inclusion Criteria
The patients diagnosed with Grade 2, and Grade 3 of oral submucous fibrosis (OSMF), as evident from their detailed clinical and histopathological examination
Exclusion Criteria
The patients with previous treatment of OSMF, patients who had Grade 1 and 4 OSMF, who were allergic to placental extract, steroids, and hyaluronidase, the patients who did not give their consents, who have syndromic or systemic disease with mouth ulcers, who had undergone radiotherapy sessions leading to oral ulcers, those who gave previous history of major surgery in the oral cavity, patients with carcinoma of oral cavity, were excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The significant increase in the mouth-opening and relief of burning sensation with combination intralesional injection therapy in OSMFTimepoint: at Baseline, 4th week, 8th week, 12th week and 12th month.
- Secondary Outcome Measures
Name Time Method The significant increase in the mouth-opening and relief of burning sensation with combination intralesional injection therapy in OSMFTimepoint: At baseline